Journal article
Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
Abstract
BACKGROUND: One-year follow-up data from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial show that use of low-molecular-weight heparin (enoxaparin) compared with unfractionated heparin in patients hospitalized with unstable angina or non-Q-wave myocardial infarction is associated with a 10% reduction in the cumulative 1-year risk of death, myocardial infarction, or recurrent angina. Given the …
Authors
O'Brien BJ; Willan A; Blackhouse G; Goeree R; Cohen M; Goodman S
Journal
American Heart Journal, Vol. 139, No. 3, pp. 423–429
Publisher
Elsevier
Publication Date
March 2000
DOI
10.1016/s0002-8703(00)90085-1
ISSN
0002-8703
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsCanadaCardiac CatheterizationCoronary Artery BypassCoronary DiseaseCost-Benefit AnalysisCritical CareEnoxaparinFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansLength of StayMaleMiddle AgedOutcome Assessment, Health CareRisk Assessment